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Abstract
Background: Mixed adenoneuroendocrine carcinomas are highly malignant tumors with both adenocarcinomatous
and neuroendocrine components. They can originate in any organ but are more common in the rectum. Due to their
rarity, current treatment recommendations for mixed adenoneuroendocrine carcinoma are based on limited data and
follow general guidelines for the management of adenocarcinomas and neuroendocrine neoplasms. Uncertainty
regarding the efficacy of the available local and systemic treatment strategies is a compounding issue. Even those
patients with locally limited disease have a relatively short life expectancy. In this report, we describe a case of deep
rectal mixed adenoneuroendocrine carcinoma with long survival after chemoradiation.
Case presentation: A 48-year-old Caucasian woman was diagnosed with a grade 3 rectal adenocarcinoma combined
with a poorly differentiated large cell neuroendocrine carcinoma component and synchronous metastases (cT3cN1cM1) in
both lobes of the liver in 2012. She received concomitant chemoradiotherapy followed by four additional cycles of cisplatin
plus irinotecan. Initial treatment induced complete remission of the rectal tumor and liver metastases. Consequently, it was
not necessary to surgically resect the primary tumor or any of the metastases. Three months after the end of treatment,
one metastasis in the first segment of the liver showed regrowth, and stereotactic body radiotherapy of the
metastasis and chemotherapy resulted in a clinical complete response. The patient has been recurrence-free
for more than 5 years.
Conclusions: Extended long-term control of a poorly differentiated metastatic (stage IV) mixed adenoneuroendocrine
carcinoma is rare. The multimodal first- and second-line regimens of radiotherapy and chemotherapy described in this
case report represent a new therapeutic approach. Encouraged by the results in this case, we compiled a review of the
literature on mixed adenoneuroendocrine carcinoma.
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Background
Colorectal mixed adenoneuroendocrine carcinomas (MAN-
ECs) are highly malignant tumors [1]. Due to their rarity,
only 1–2% of neuroendocrine tumors (NETs) of the large in-
testine are MANECs [2], and very few publications about
these tumors exist. General treatment guidelines for these
tumors with this mixed histology are lacking. According to
the colorectal neuroendocrine carcinoma (NEC) guidelines
issued by the European Neuroendocrine Tumor Society
(ENETS), local treatment of metastatic MANEC is indicated
in only a few cases, and metastatic MANEC has a poor
prognosis [3]. The National Comprehensive Cancer Net-
work guidelines for NETs, however, recommend surgical re-
section of metastases [4] based on a review of multiple NEC
cases [5]. Surgery and radiotherapy are established modal-
ities for the treatment of colorectal cancer and NETs in
other locations, but scientific reports of explicit clinical
experience validating their efficacy in the treatment of
MANECs, especially metastatic stage MANECs, are still
lacking.
In this report, we describe a case of a patient with
metastatic MANEC treated by concurrent chemoradio-
therapy (CRT) that resulted in long-term disease control.
This case shows that local therapy, in particular CRT,
should be considered in addition to sole polychemother-
apy, even in poorly differentiated and metastatic
MANEC, because of the curative potential.
Case presentation
A 48-year-old Caucasian woman, Eastern Cooperative
Oncology Group (ECOG) performance status 1, was di-
agnosed with locally advanced rectal carcinoma infiltrat-
ing the dental line with lymph node metastases. She was
diagnosed by computed tomography (CT) (Fig. 1a) and
Fig. 1 Deep seated, wall-penetrating rectal carcinoma (a, arrow, magnetic resonance imaging (MRI) with multiple bilateral liver metastases (b, arrow,
computed tomography (CT) before treatment in April 2012. The patient reached partial remission after two cycles of cisplatin/irinotecan (c, residual
metastasis in segment I with an arrow, CT) in June 2012 and complete remission after six cycles (d, arrow: no evidence of macroscopic metastasis in
segment I, CT) in October 2012. View of segment I showing post-treatment recurrence in February 2013 (e, arrow, MRI) and status 5 years after
stereotactic body radiotherapy and chemotherapy in February 2018 (f, no evidence of vital tumor: arrow, MRI)
Semrau et al. Journal of Medical Case Reports           (2019) 13:82 Page 2 of 8
proctoscopy (no image available) after presenting with
problems with defecation, constipation, and tumor-re-
lated anemia (see Table 1 for treatment timeline). In fact,
painful stenosis prevented endoscopic ultrasound. Sig-
nificant preexisting diseases were not known, except
hypothyroidism or any history of cancer in close family
members. She had no occupational noxae. She did not
smoke or drink substantial quantities of alcohol. Histo-
logical examination of a biopsy specimen of the tumor,
which occupied the entire circumference of the rectum,
revealed a poorly differentiated adenocarcinoma with a
large cell NEC component (Fig. 2a) confirmed by strong
diffuse staining for synaptophysin and CD56 (Fig. 2b)
and comprising > 30% of the tumor in the biopsy mater-
ial. The result of chromogranin A testing was negative.
The patient’s Ki67 index was > 80%. Histology of the
NEC component was consistent with grade 3 (G3) NEC
of large cell type (Fig. 2c). More than ten metastases
were also detected in both lobes of the liver by CT scan
(Fig. 1b), so the patient’s TNM stage was cT3cN1cM1.
The patient received a regimen of cisplatin (CDDP; 20
mg/m2 on days 1–5, every 4 weeks) in combination with iri-
notecan (IRI; 50mg/m2/day on days 1/8/15, every 4 weeks),
an agent known for its efficacy in both colorectal cancer and
NEC [6, 7]. In parallel, conventionally fractionated pelvic
radiotherapy up to 50.4 Gy (reference point dose,
intensity-modulated radiation therapy) was performed with
the primary goal of alleviating pain and preventing obstruc-
tion by achieving maximum response. Initially, the patient
received a red blood cell transfusion and sodium picosulfate
against constipation. For antiemetic prophylaxis during all
chemotherapy cycles, she received aprepitant (125mg/day,
d1; 80mg/day, d2–5), ondansetron (16mg/day), dexametha-
sone (12mg/day, d1; 8mg/day, d2–5), and pantoprazole 40/
mg/day and enoxaparin sodium 40mg/day.
At the end of chemoradiation, the patient experienced
rectal pain, which was treated with tramadol (3 × 100 mg/
day), and fatigue. Parenteral nutrition was required because
of diarrhea (Common toxicity Criteria for Adverse Events
version 5.0 [CTC] grade III) and dehydration (CTC grade
III). The patient had port-related sepsis (Staphylococcus epi-
dermidis in blood culture), which was successfully treated
with vancomycin (2 × 1 g/day, intravenous), and a urinary
tract infection (Escherichia coli), which was treated with cip-
rofloxacin (2 × 400 mg/day, intravenous). She needed red
cell blood transfusions for anemia during the first cycle
(CTC grade III) (see Table 2) and filgrastim 480μg/0.5ml for
6 days for the treatment of leukopenia (CTC grade IV) at
the end of the second cycle of chemotherapy. There were
no unexpected events or clinical examination results. A
summary of relevant laboratory parameters at baseline and
during treatment is provided in Table 2.
As the CT examination performed immediately after
the end of radiotherapy showed only partial remission of
the liver metastases (Fig. 1c), four additional cycles of
modified CDDP/IRI (CDDP 20mg/m2 on days 1–4,
every 4 weeks; IRI 50 mg/m2/day on days 1/8/15, every 4
weeks) with prophylactic treatment mentioned above
were administered after the end of chemoradiotherapy.
No toxicity CTC grade III or IV was observed, but the
patient had temporary need of a fentanyl patch for rectal
pain treatment. Ultimately, she had ECOG I with no
pathologic findings in the physical and neurological
examinations.
In light of clinical complete remission of the deep rec-
tal cancer and improvement of rectal stenosis, confirmed
by simple proctoscopy with direct visualization, surgical
resection was not performed, owing to uncertainty re-
garding the chances of preserving fecal continence.
Complete remission of the liver metastases seen in the
CT scan was also achieved after a total of six cycles of
CDDP/IRI (Fig. 1d).
Recurrence of an initial metastasis in segment I was
detected after a treatment-free interval of 3 months
(Fig. 1e). Examination of a liver biopsy specimen re-
vealed poorly differentiated NEC (Fig. 2d). The patient
underwent eight new cycles of CDDP/IRI (CDDP 20mg/
m2 d1–3; IRI 60 mg/m2 d1, d8, d15; cycles IV to VIII
with 60% of the dose) with the same prophylactic treat-
ment and stereotactic body radiotherapy of the liver me-
tastasis within the first cycle of chemotherapy. The
fractionation scheme was 15 × 3 Gy (reference point
dose), 60 Gy (equivalent dose in 2-Gy fractions with α/β
= 10). During this treatment, there was a port infection
(CTC grade III, S. epidermidis) treated with vancomycin
(2 × 1 g/day, intravenous), but no other higher-grade
toxicity or relevant neurologic or physical findings dur-
ing hospital stay or outpatient visits, which took place at
least once per week.
Treatment resulted in complete remission of the me-
tastasis (Fig. 1f ). Serum neuron-specific enolase, an in-
dependent marker of overall survival of NETs (upper
limit of normal, 17.49 ng/ml), also decreased in parallel
with the treatment cycles (Fig. 3).
The patient was followed up by CT scan of the chest
and abdomen, as well as MRI of the liver every 6
months, and was tumor-free and symptom-free for 5
years and had no signs of impaired liver function or late
toxicity after rectal radiotherapy. Results of all clinical
and laboratory investigations remained unremarkable
(Table 2). The patient’s last follow-up examination was
in the autumn of 2018.
Discussion
Our patient’s case demonstrates that excellent long-term
results can be achieved by using a combination of local and
systemic therapy in first- and second-line treatment of
MANECs, even in cases with multiple synchronous visceral
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metastases of the NEC component, when success is mea-
sured in terms of organ preservation and systemic disease
control over several years. To the best of our knowledge,
this is the first time that such a successful long-term out-
come has been reported in the literature. Due to the rarity
of the disease, this has implications for treatment planning
in similar cases.
Such information is particularly important because, al-
though rare, NETs and carcinomas of the rectum are be-
ing diagnosed in increasing numbers. Their incidence has
been steadily rising for decades; for instance, from 0.1 per
1,000,000 persons in 1973 to 1.0 per 100,000 in 2014 [8].
Although the percentage of MANECs within this group of
tumors is low, their incidence can be expected to rise as
awareness of this tumor entity increases.
MANECs represent an aggressive subgroup in the
spectrum of mixed neuroendocrine-nonneuroendocrine
neoplasms. According to the current World Health
Organization classification of neuroendocrine neo-
plasms, both tumor components must make up at least
30% of the tumor [9]. The MANEC components may
present two distinctive separated components within a
single gross mass (collision tumor-like), blend with each
other (composite tumors), or (less commonly) show dual
(amphicrine-type) differentiation within the same cells.
Diagnosis based on biopsy specimens might be impossible
if only a single component is represented. Although both
components can/should be graded, the neuroendocrine
component is usually prognostically limiting, and it corre-
sponds to poorly differentiated NEC of either small cell
type (less frequently) or large cell type; our patient had the
latter type [1]. The large and small cell pattern of the NEC
in MANEC corresponds to the most frequent pulmonary
counterparts. Very rarely, the neuroendocrine component
may display a well-differentiated morphology (NET
morphology) and should be graded on the basis of Ki67
index similar to pure NETs of the gastroenteropancreatic
system into NET G1 (Ki67 < 3%), NET G2 (Ki67 3–20%),
or rarely NET G3 (Ki67 > 20%). Although Ki67 is usually
very high in NEC (from > 50% to 100%), their classifica-
tion is mainly morphology-based (poor cytological and
architectural differentiation) and not on the basis of their
high Ki67 index.
The prognostic relevance of the different tumor types
and grades is not clear yet. In this sense, MANECs differ
from other pure NETs. Especially if in the metastatic
Fig. 2 Findings of histological examination of the rectal tumor
specimen. a Tumor with a small glandular component (hematoxylin
and eosin stain (H&E stain)), adenocarcinoma (thin arrow), and a
dominant neuroendocrine component (thick arrow). The neoplasm
was CD56-positive (b) and had a high Ki67 proliferation index > 80%
(c). An identical histologic pattern was seen in the liver metastasis
(hematoxylin and eosin stain (H&E stain), d)
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stages, patients with MANEC generally have very poor
survival, regardless of whether the neuroendocrine com-
ponent has a low or high proliferative index [10].
MRI for the diagnosis of lymph node metastasis is pre-
sumably less sensitive for MANECs than for pure adeno-
carcinomas [11].
As no study- or guideline-based general treatment rec-
ommendations for mixed NECs exist, clinicians look to
recommendations for colorectal cancer and NEC for
guidance. This has led to critical discussions regarding
the necessary extent of surgery, the need for radiother-
apy, and the type of chemotherapy.
The rationale for using a combination of local therapy
(radiotherapy for preservation of the sphincter content)
and chemotherapy with CDDP plus IRI in our patient
was based on the fact that her complaints had both a
prognostically relevant systemic component and a local
component.
If metastases are present, they may contain one or
both of these histological features [12]. 5-Fluorouracil
Table 2 Eastern Cooperative Oncology Group Performance Status and laboratory data at diagnosis, during treatment, two month
after treatment and last follow up at 69 month
Diagnosis in 2012 Month
1–2
after 2
month
Month
3–6
after 6
month
Month
6–9
after 9
month
Month
11 + 12
Month
13–21
Month
23
Month
69
ECOG Performance Status
1 2 2 1 1 0 0 0 2 0 0
Laboratory Data at the start of treatment, during the treatment as maximum toxicity, restaging and last follow
White blood cell (×103 /μl) 7.5 0.6 3.8 1.4 2.2 3.6 4.6 6.6 1.5 6.6 8.7
Hemoglobin (g/dl) 8.8 7.2 10.0 8.4 8.2 10.9 13.3 10.0 8.8 11.9 10.6
Red blood cell (× 106 /μl) 4.3 2.6 3.4 2.7 2.6 3.1 4.1 3.0 2.5 3.6 4.1
Platelet (×103 /μl) 431 74 144 178 240 225 289 209 113 245 491
Creatinine (mg/dl) 0.83 1.42 1.48 1.33 0.85 1.00 0.77 1.09 1.03 1.08 0.98
AST (U/l) 214 52 21 79 32 43 26 36 37 25 16
ALT (U/l) 129 117 16 118 30 50 22 41 53 18 17
Total Bili (mg/dl) 0.8 0.7 0.3 0.9 0.4 0.5 0.4 0.7 0.5 0.3 0.4
GGT (U/l) 50 176 62 70 31 37 24 91 123 36 16
Albumin (g/l) 34.4 22.7 30.9 30.9 40.7 34.9 45.9 33.9 29.3 42.1 38.5
INR 1.0 0.99 1.01 1.01 1.03 1.03 – 0.98 0.99 – 0.95
Fig. 3 Neuron-specific enolase (NSE) tests showed peak levels before treatment and at the time of metastasis recurrence. Low levels were
reached after first chemoradiation (CRT) at the time of complete response (CR) and after second chemoradiation of the liver metastasis
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forms the backbone of the established chemotherapeutic
regimen for the treatment of metastatic carcinomas of
the rectum, and it tends to be recommended in cases
where the adenocarcinoma component is the only con-
stituent detected [13]. If there are metastases exhibiting
neuroendocrine differentiation, a regimen of CDDP plus
either etoposide or IRI (such as that used in small cell
lung cancer [SCLC]) can be used, which is reported to
achieve a response rate of 40% [14] and 50% [10], re-
spectively. Theoretically, if the rate of proliferation is
low, a higher probability of somatostatin receptor ex-
pression can be expected, and treatment with an octreo-
tide analog [15], mammalian target of rapamycin
inhibitor [16], sunitinib [17], or lutetium-177 dotatate
[18] would be conceivable, analogous to NET treatment.
In view of our patient’s high proliferation index, we de-
cided to use a combination of CDDP and IRI. This regi-
men was also selected with the secondary goal of
radiosensitivity in mind. Here, the goal of concurrent
chemoradiation was to quickly alleviate problems at the
site of the most severe complaints.
Recommendations for local therapy of localized
MANEC range from simple local excision analogous to
the procedure for early rectal carcinoma to oncological
rectal resection [4, 13]. The ENETS guidelines for gas-
troenteropancreatic NETs also allow for combination
treatments [19].
In the case of metastatic NEC, however, the need for
surgery is relativized by the fact that even those patients
with locally limited disease have lower chances of sur-
vival than those with rectal adenocarcinomas. Wang et
al. [20], for example, found that only 50% of patients
with localized MANECs survived 2 years after surgical
resection due to the rapid onset of distant metastasis.
Definitive chemoradiotherapy has not yet been discussed
as an alternative form of treatment or, if at all, only as
neoadjuvant chemotherapy. Tanaka et al. [13], for ex-
ample, described the case of a 54-year-old patient with
MANEC (female) who developed tumor regression after
neoadjuvant chemoradiotherapy followed by surgical re-
section. Our patient developed a complete response to
chemoradiotherapy, which made it possible to dispense
with surgical resection and, thus, to preserve the rectum,
including the anal sphincter muscle. This outcome had
not been reported previously for MANEC but cannot be
regarded as unusual in light of the known curative effect
of chemoradiotherapy in SCLC. In agreement with this
hypothesis, in 2017, Voong et al. reported ten cases of
pure NEC of the anus and rectum treated with chemora-
diation. Locoregional control was achieved for the ma-
jority of patients for their remaining lifetime, but all
developed distant metastases [21].
Two unexpected findings in our patient were the
long-term remission of liver metastases in response to
chemotherapy alone and the fact that no further metas-
tases developed. The progression of a single, known le-
sion made it necessary to administer local therapy.
In view of the location of the primary tumor, its good
response to chemoradiotherapy, the limited prospects of
complete therapy, and the unfavorable location of the
metastases, we opted to perform stereotactic body radi-
ation therapy instead of surgical resection or radiofre-
quency ablation. This therapeutic approach resulted in
local control of metastases without impairment of liver
function [22, 23]. The advantages of this approach are
obvious, and equivalent methods have not been reported
to date.
Conclusions
This case demonstrates that patients with MANEC can
have a good outcome. Our results suggest that even in
patients with MANEC with a poorly differentiated neu-
roendocrine component and metastases, it is reasonable
to attempt a local therapy regimen analogous to that
used in rectal cancer as an approach to achieve primary
tumor control, provided the number of distant metasta-
ses is small.
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